Nanocarrier Vaccines for SARS-CoV-2

Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar, Lalit K. Vora, Tapan A. Patel, Maxim D. Oleynikov, Dhruvkumar Soni, Pravin Yeapuri, Insiya Mukadam, Rajashree Chakraborty, Caroline G. Saksena, Jonathan Herskovitz, Mahmudul HasanDavid Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

The SARS-CoV-2 global pandemic has seen rapid spread, disease mobidities and death associated with substantive social, economic and societal impact. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and elimination and the principal global effort with success now being realized. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.
Original languageEnglish
JournalAdvanced Drug Delivery Reviews
Early online date09 Jan 2021
DOIs
Publication statusEarly online date - 09 Jan 2021

Fingerprint Dive into the research topics of 'Nanocarrier Vaccines for SARS-CoV-2'. Together they form a unique fingerprint.

Cite this